Elevation Oncology IPO Raises $115M
June 24, 2021 – Elevation Oncology, Inc. (NASDAQ: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $16.00…Read More
Read MoreVera Therapeutics IPO Raises $47.8M
May 13, 2021 – Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00…Read More
Read MoreCompass, Inc. IPO Raises $450M
April 1, 2021 – Compass, Inc. completed its Initial public offering of 25,000,000 of Class A common stock, to begin trading on the NYSE under the symbol COMP. The IPO shares were priced at $18/share. Lead underwriters were Goldman Sachs, Morgan Stanley. and Barclays Capital Inc. The FLG partners Jennifer…Read More
Read MoreJumio Raises $150M in Private Equity
March 23, 2021 – Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, today announced it secured a $150 million investment from Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies. FLG partner Kenton Chow assisted. Full press release is here.
Read MoreConnect Biopharma IPO Raises $220M
March 18, 2021 – Connect Biopharma Holdings Limited announced its initial public offering of 11,250,000 American Depositary Shares (“ADSs”), representing 11,250,000 ordinary shares of the Company, at a public offering price of US$17.00 per ADS. FLG partner Eric Hall assisted. Company press release.
Read More